Reply to ‘Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Annals of Oncology 2007, vol 18, Suppl 3, pp1-75)’ by Michel P Coleman-Reference-Cited by-同舟云学术

Reply to ‘Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Annals of Oncology 2007, vol 18, Suppl 3, pp1-75)’ by Michel P Coleman

Published:2007-09 Issue:9 Volume:18 Page:1585-1587
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Jönsson B.,Lichtenberg F.,Wilking N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/9/1585/539230/mdm397.pdf

Reference5 articles.

1. A global comparison regarding patient access to cancer drugs;Jönsson;Ann Oncol,2007

2. Measuring the gains from medical research. An economic approach;Murphy,2003

3. The Return on Investment in Health Care: From 1980–2000;Luce;Value in Health,2006

4. Substantial Returns to Health care Spending: But Do We Spend to Little or Too Much?;Buxton;Value in Health,2006

5. The impact of new drug launches on longevity: evidence from longitudinal disease level data from 52 countries, 1982–2001;Lichtenberg;Int J Health care Finance Econ,2005

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Die Messung der Kosten von Krebserkrankungen in Deutschland;Forum;2021-12-07

2. Cancer costs and outcomes for common cancer sites in the Finnish population between 2009–2014;Acta Oncologica;2018-02-16

3. Cancer costs and outcomes in the Finnish population 2004–2014;Acta Oncologica;2017-07-11

4. Ressourcenallokation in der Onkologie;Der Onkologe;2015-07-08

5. Cancer Mortality Reductions Were Greatest Among Countries Where Cancer Care Spending Rose The Most, 1995–2007;Health Affairs;2015-04